The program for diagnosing a germline mutation in the BRCA1/2 genes and for preventative strategies, aimed at family members of patients diagnosed with ovarian cancer, proved to be a cost-effective alternative, from the perspective of the National Health System. The gene discussed is BRCA1; the disease is ovarian cancer.